For patients with chronic kidney disease, which SGLT2 inhibitor (dapagliflozin or empagliflozin) is preferred?

Medical Advisory BoardAll articles are reviewed for accuracy by our Medical Advisory Board
Educational purpose only • Exercise caution as content is pending human review
Article Review Status
Submitted
Under Review
Approved

Last updated: August 21, 2026 • View editorial policy

Have a follow-up question?

Our Medical A.I. is used by practicing medical doctors at top research institutions around the world. Ask any follow up question and get world-class guideline-backed answers instantly.

Both SGLT2 Inhibitors Are Equally Effective for CKD

For patients with chronic kidney disease, either dapagliflozin or empagliflozin can be used with equivalent clinical benefit—choose based on eGFR thresholds and local availability rather than superiority of one over the other.

Evidence-Based Equivalence

The most recent and authoritative guidelines explicitly state that both agents are acceptable options. The 2024 BMJ clinical practice guideline for CKD management lists "canagliflozin, dapagliflozin, and empagliflozin" as SGLT2 inhibitors that "may be considered for use in individuals with CKD" without distinguishing superiority among them 1. The 2022 ADA/KDIGO consensus similarly supports both agents based on landmark trials 2.

Key Trial Evidence

Both drugs demonstrated robust kidney protection in their respective pivotal trials:

  • DAPA-CKD (dapagliflozin): Enrolled 4,304 CKD patients with eGFR 25-75 mL/min/1.73 m² 3
  • EMPA-KIDNEY (empagliflozin): Enrolled >6,600 CKD patients with eGFR ≥20 mL/min/1.73 m² 2

Both trials were stopped early for overwhelming efficacy, showing reductions in:

  • All-cause mortality
  • Kidney failure progression
  • Cardiovascular events
  • Hospitalization for heart failure

Direct Comparative Evidence Shows No Clinically Meaningful Difference

The highest quality head-to-head comparison is a 2025 Danish nationwide target trial emulation with 50,283 patients followed for up to 6 years 4. This study found no significant differences in:

  • Acute kidney injury (18.2% vs 18.5%; RR 0.98)
  • Incident CKD stages G3-G5 (11.8% vs 12.1%; RR 0.97)
  • CKD progression (5.3% vs 5.7%; RR 0.94)

A 2024 network meta-analysis of 21 RCTs with 96,196 participants confirmed "differences in reducing cardiovascular and kidney outcomes...across SGLT2 inhibitors were not consistently significant" 5.

Contradictory Evidence Requires Context

One 2026 retrospective cohort study (N=53,887) suggested empagliflozin had lower rates of stage 5 CKD/ESKD (HR 0.84) 6. However, this conflicts with the more rigorous 2025 Danish study 4 and likely reflects residual confounding in observational data. Prioritize the prospective trial emulation over retrospective cohorts.

Practical Selection Algorithm

Choose Based on eGFR Thresholds:

Dapagliflozin:

  • Initiate if eGFR ≥25 mL/min/1.73 m² 2, 3
  • Continue if eGFR falls below 25 until dialysis 3
  • FDA-approved down to eGFR 25 3

Empagliflozin:

  • Initiate if eGFR ≥20 mL/min/1.73 m² for heart failure indication 2
  • For glycemic control alone: not recommended <30 mL/min/1.73 m² 2
  • Broader initiation threshold in heart failure patients 2

Special Populations:

Diabetic vs Non-Diabetic CKD:

  • Both equally effective regardless of diabetes status 2, 4
  • One cost-effectiveness analysis suggested empagliflozin may have better value in diabetic patients, dapagliflozin in non-diabetic patients 7, but this should not drive clinical decisions

With vs Without Albuminuria:

  • EMPA-KIDNEY demonstrated empagliflozin benefits even without albuminuria 2
  • Both agents work across albuminuria categories

Common Pitfalls to Avoid

  1. Don't discontinue when eGFR declines acutely: The initial eGFR dip (2-4 mL/min) is hemodynamic and reversible—continue therapy unless dialysis initiated 2

  2. Don't wait for severe CKD: Initiate at eGFR ≥25 (dapagliflozin) or ≥20 (empagliflozin for HF) rather than waiting for further decline 1, 2

  3. Don't assume one is "stronger": Marketing and local prescribing patterns may create false impressions of superiority—evidence shows equivalence 4, 5

  4. Monitor for volume depletion: Both require assessment of volume status before initiation, particularly in elderly patients or those on diuretics 2

  5. Institute sick day protocols: Hold during acute illness to prevent ketoacidosis and volume depletion 2

Bottom Line

Select either dapagliflozin or empagliflozin based on eGFR thresholds, formulary availability, and cost rather than perceived efficacy differences. If eGFR is 25-29 mL/min/1.73 m², dapagliflozin has more robust FDA approval for CKD indication 3. If eGFR is 20-24 mL/min/1.73 m² with heart failure, empagliflozin may be preferred 2. Otherwise, they are interchangeable for kidney protection 4, 5.

Professional Medical Disclaimer

This information is intended for healthcare professionals. Any medical decision-making should rely on clinical judgment and independently verified information. The content provided herein does not replace professional discretion and should be considered supplementary to established clinical guidelines. Healthcare providers should verify all information against primary literature and current practice standards before application in patient care. Dr.Oracle assumes no liability for clinical decisions based on this content.